Background-The molecular mechanism by which catecholaminergic polymorphic ventricular tachycardia is induced by single amino acid mutations within the cardiac ryanodine receptor (RyR2) remains elusive. In the present study, we investigated mutation-induced conformational defects of RyR2 using a knockin mouse model expressing the human catecholaminergic polymorphic ventricular tachycardia-associated RyR2 mutant (S2246L; serine to leucine mutation at the residue 2246). Methods and Results-All knockin mice we examined produced ventricular tachycardia after exercise on a treadmill.
R yanodine receptor (RyR2), the Ca 2ϩ release channel in the cardiac sarcoplasmic reticulum (SR), plays a key role in cardiac excitation-contraction coupling. 1 A considerable body of evidence shows that RyR2 function is defective in failing hearts, causing spontaneous Ca 2ϩ leak. 2 The Ca 2ϩ leak leads to contractile dysfunction by reducing the SR Ca 2ϩ content and also induces delayed afterdepolarization, which ultimately leads to lethal arrhythmia. 2 More than 120 RyR2 mutations have been identified in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) or arrhythmogenic right ventricular cardiomyopathy type 2. 3 RyR2 mutations are not randomly distributed, but they cluster into 3 definable regions. These domains are designated as the N-terminal domain (amino acids 1 to 600), the central domain (amino acids 2000 to 2500), and the C-terminal channel-forming domain. Because a single point mutation in any of these domains has a severe impact on the channel function, these domains must play a key role in regulating the channel function of both RyR2 and RyR1.
Clinical Perspective on p 694
Chiefly on the basis of the conformational probe approach, Ikemoto and colleagues 4 -6 proposed that the N-terminal domain and the central domain interact with each other to act as the implicit on/off switch that opens and closes the channel, and the interacting domain pair was designated as a "domain switch." Parallel assays of the conformational state of RyR2 and the functional state of Ca 2ϩ channel have shown that zipping of the interacting domains closes the channel, and unzipping opens it. A mutation in either domain weakens the interdomain interaction and causes domain unzipping in an otherwise resting state, which results in an erroneous activation of the channel and diastolic Ca 2ϩ leak. 4 -6 Consistent with the domain switch hypothesis, single-particle analysis of the 3-dimensional structure of the RyR2 molecule revealed that the N-terminal and central domains (located in domains 5 and 6 of the so-called clamp region, respectively) are in close apposition to each other. 7, 8 We have shown previously that in failing hearts, defective interaction between the N-terminal domain and the central domain of RyR2 induces Ca 2ϩ leak even under the conditions of reduced SR Ca 2ϩ load, leading to contractile dysfunction. 9 In normal hearts, these domains interact with each other to produce a zipped configuration, which stabilizes the closed state of the Ca 2ϩ channel. However, in the failing heart, this interaction becomes loose because of oxidative stress 10 or protein kinase A (PKA)-mediated hyperphosphorylation and dissociation of FKBP12.6. 9 Domain unzipping destabilizes the closed state of the channel, resulting in diastolic Ca 2ϩ leak. We have also shown that correcting the unzipped configuration to the normal zipped state by treatment with either K201 (JTV519) 9, 11 or dantrolene 12 restores normal channel gating in otherwise leaky RyR2 channels of failing hearts.
Moreover, we recently demonstrated, using a transgenic mouse model in which CPVT-type R2474S mutation is knocked in the central domain of RyR2, that this mutation caused aberrant unzipping of the domain switch regions, lowering the threshold of luminal [Ca 2ϩ ] for channel activation, sensitizing the channel to PKA-dependent phosphorylation, and led to CPVT. 13 Dantrolene treatment that corrects the defective interdomain interaction prevented aberrant Ca 2ϩ release, thereby preventing delayed afterdepolarization and CPVT. 13, 14 These findings indicate that the defective interdomain interaction between the N-terminal and central domains, caused by single point mutation, oxidative stress, and/or PKA hyperphosphorylation, destabilizes the channel, leading to lethal arrhythmia and heart failure.
In our previous study of canine RyR2, we found that the domain switch is conformationally coupled with the interaction of subdomains (the 2114 to 2149 region and the 2234 to 2750 region) within the central domain, playing an important role in the regulation of channel function: Their tight interaction (subdomain zipping) opens the Ca 2ϩ channel, and their dissociation (subdomain unzipping) closes the channel. 11 We then demonstrated several important features of the interaction: (1) Diastolic SR Ca 2ϩ leak of failing heart happens as a result of erroneous zipping of these subdomains and channel activation in an otherwise resting state; (2) specific binding of K201 to RyR2 takes place at the 2114 to 2149 region, indicating that this is the K201-binding domain; and (3) the binding of K201 to this domain interferes with its interaction with the 2234 to 2750 region, thereby correcting aberrant domain zipping and diastolic Ca 2ϩ leak in the failing RyR2. 11 The aforementioned findings suggest the hypothesis that the S2246L (serine to leucine mutation at residue 2246) CPVT mutation in the 2234 to 2750 region (which we call 2246 domain) causes an abnormal zipping between the 2246 domain and the K201-binding domain. To test this hypothesis, we used S2246L knockin mice. We demonstrate here that the S2246L mutation introduced into the 2246 domain causes an abnormally tight interaction with its partner domain (the K201-binding domain). Importantly, this mutation-induced tight zipping of these domains is coupled in an allosteric manner with unzipping of the domain switch. This leads to several phenotypes such as hypersensitized channel gating to luminal [Ca 2ϩ ] and to increased diastolic Ca 2ϩ leak, the phenotypes that are commonly observed in the transgenic mouse models carrying different knockin CPVT mutations, [15] [16] [17] including our previously investigated R2474S/ϩ knockin model. 13
Methods
An expanded Methods section is available in the online-only Data Supplement.
Animals
This study conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996). The care of the animals and the protocols used were in accord with guidelines laid down by the Animal Ethics Committee of Yamaguchi University School of Medicine.
Peptides Used and Peptide Synthesis
We used the 3 domain peptides (DP), as described previously 13 : (1) DPc10: DP2460-2495; 2460GFCPDHKAAMVLFLDRVY-GIEVQDFLLHLLEVGFLP2495; (2) DP2246:DP2232-2266; 2232-PAMRGSTPLDVAAASVMDNNELALALREPDLEKVV2266; and (3) DP2246mut:DP2232-2266mut (serine2246 is mutated to leucine); 2232PAMRGSTPLDVAAALVMDNNELALALREPDLEKVV2266.
Analysis of Local Ca 2؉ Release Events
The local Ca 2ϩ release events were measured in saponin-permeabilized cardiomyocytes, as described previously. 13 To avoid possible side effect of Ca 2ϩ /calmodulin-dependent protein kinase II (CaM-KII) on cAMP-induced change in Ca 2ϩ sparks, CaMKII inhibitor KN-93 (1 mol/L) was added.
Statistical Analysis
Paired or unpaired t test was used for statistical comparison of the data between 2 different situations, and ANOVA with a post hoc Scheffé test was used for statistical comparison of concentrationdependent data. Data for each different condition were obtained in the same preparation of SR or isolated cells originating from 10 to 16 hearts or 1 heart, respectively. Statistical comparison of data for these preparations was then performed. Data are expressed as meanϮSE. We accepted a P value Ͻ0.05 as statistically significant.
Results

No Appreciable Change in Structural and Functional Characteristics of S2246L/؉ Knockin Mice at the Resting State
The hearts of wild-type (WT) and knockin mice showed no appreciable anatomic and histological abnormalities under baseline conditions ( Figure IIA 
Exercise or Epinephrine Induces Ventricular Tachycardia in S2246L/؉ Knockin Mice, and Dantrolene Prevents Tachycardia
As shown in the ECG characteristics obtained from WT and knockin mice by telemetry ( Table I in the online-only Data Supplement), there was no statistically significant difference in baseline parameters of heart rate, QT interval, and QTc between WT and knockin mice. Ventricular tachycardia (VT) was not observed in the resting condition (without stress) in WT or knockin mice. However, either treadmill exercise or epinephrine injection induced bidirectional or polymorphic VT in all knockin mice we examined but not in any of the WT mice tested ( Figure 1A ). In knockin mice, pretreatment with daily intraperitoneal injection of 20 mg/kg dantrolene (7 to 10 days) prevented the VT ( Figure 1B ). Moreover, dantrolene significantly increased the total running distance during treadmill (treated: 178Ϯ55.3 m versus untreated: 59Ϯ10 m; PϽ0.01). On the other hand, pretreatment with K201 (JTV519) was without effect on the inducible VT ( Figure 1B ).
S2246L Mutation Reduces the Threshold of SR Ca 2؉ Load for Channel Activation
There was no appreciable difference in the level of PKA phosphorylation of RyR2 at Ser2808 between knockin and WT cardiomyocytes, both without and with added cAMP. The added cAMP was washed away to prevent further PKA phosphorylation ( Figure 2A ). The frequency of Ca 2ϩ sparks increased with an increase of the concentration of cAMP (0.1 to 1 mol/L) in both knockin and WT cardiomyocytes to a comparable degree ( Figure 2B ). However, because there was a considerable reduction in the SR Ca 2ϩ content in knockin cardiomyocytes, the Ca 2ϩ spark frequency per the releasable SR Ca 2ϩ content was significantly higher in knockin cardiomyocytes than in WT cardiomyocytes. As a result, the plot of Ca 2ϩ spark frequency versus SR Ca 2ϩ content shows a considerable left shift compared with that of WT cardiomyocytes ( Figure 2C ). Even under the conditions in which the SR Ca 2ϩ content was progressively reduced in the presence of thapsigargin (without cAMP), an inhibitor of SERCA2a, the SR Ca 2ϩ -dependent increase of Ca 2ϩ spark frequency was significantly higher in the knockin compared with the WT cardiomyocytes ( Figure 2C ); the increase of Ca 2ϩ spark frequency was accompanied by the increase in both full width at half maximum and full duration at half maximum at matched SR Ca 2ϩ content ( Table II in the online-only Data Supplement). The effects of cAMP on Ca 2ϩ spark characteristics of knockin cardiomyocytes are summarized in Table III in the online-only Data Supplement. In the knockin cardiomyocytes, the peak amplitude and full width at half maximum decreased, and the full duration at half maximum increased, suggesting a delay in RyR2 inactivation. Taken together, these data suggest that the thresholds of SR luminal [Ca 2ϩ ] for channel opening and for channel inactivation decreased considerably in the knockin cardiomyocytes because of the single S2246L mutation in RyR2.
PKA phosphorylation modulates not only RyR2 Ca 2ϩ release but also SR Ca 2ϩ uptake. Thus, we measured the Ca 2ϩ spark frequency and SR Ca 2ϩ content in the presence of 0.3 mol/L thapsigargin ( Figure 2D ). Thapsigargin eliminated the cAMP-dependent Ca 2ϩ spark frequency increase in both WT and knockin cardiomyocytes. This suggests that the cAMP-dependent Ca 2ϩ spark frequency increase is primarily due to the activation of SR Ca 2ϩ uptake and subsequent increase in SR Ca 2ϩ load.
To determine whether preventing unzipping of the domain switch (see Introduction) reverses the leftward shift of the Ca 2ϩ spark frequency/SR Ca 2ϩ content dependence seen in the knockin cardiomyocytes, we used dantrolene, which was shown to bind to residues 602 to 620 of RyR2 and prevent both domain unzipping and abnormal Ca 2ϩ release in failing hearts. 12 Dantrolene shifted the Ca 2ϩ spark frequency/SR Ca 2ϩ content plot to the right, resulting in a WT-like pattern ( Figure 2E ). However, K201, which prevented the development of heart failure, 18 did not correct the leftward shift of the Ca 2ϩ spark frequency/SR Ca 2ϩ content dependence in knockin mouse cardiomyocytes ( Figure 2F ; for the reason, see Discussion).
Probing the 2246 Domain/ K201-Binding Domain Interaction With DP2246 (a Domain Peptide Corresponding to the 2246 Domain)
To localize the partner domain to which DP2246 binds, we first labeled RyR2 using the peptide-mediated site-directed methylcoumarin acetamido (MCA) labeling technique. 6, 9 Then the MCA-labeled RyR2 was subjected to tryptic digestion to analyze the degradation of the fluorescently labeled polypeptide chain by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunomapping with site-specific antibodies. As shown in Figure 3A , DP2246-mediated photoaffinity labeling of the fluorescent probe MCA resulted in specific fluorescent labeling of RyR2. The presence of an excess concentration of unlabeled DP2246 (10 mmol/L) prevented DP2246-mediated MCA labeling. Ab2141 (an antibody raised against the K201-binding domain), but not nonimmune IgG, prevented DP2246-mediated MCA labeling. These results indicate that DP2246 binds specifically to the K201-binding domain.
The MCA-labeled RyR2 polypeptide chain was degraded to 210-, 155-, 125-, and then to 60-kDa fragments, all of which were immunostained with Ab2141, an antibody directed against the central region ( Figure 3B ). Furthermore, of several recombinant RyR2 fragments, which span residues 1 to 2750, only the fragment 1741 to 2270 was specifically labeled with MCA ( Figure 3C ). These data suggest that DP2246 interacts with the 1741 to 2270 region of RyR2, which includes the previously reported 2114 to 2149 K201binding domain. 11 To further verify the DP2246-binding domain of RyR2, we used the quartz crystal microbalance binding assay as an in vitro model of domain-domain interaction. As shown in Figure 4A , DP2246 rapidly bound to fragment 1741 to 2270 but not to other recombinant fragments. Ab2141, but not nonimmune IgG, abolished DP2246 binding to fragment 1741 to 2270 ( Figure 4B ). This further supports the notion that DP2246 binds to the K201-binding domain (residue 2114 to 2149) within the 1741 to 2270 residue region.
S2246L Mutation Increases the Affinity of Binding of DP2246 to RyR2
As the first approach to test the hypothesis that the S2246L CPVT mutation in the 2246 domain causes an abnormal zipping between the 2246 domain and the K201-binding domain (see Introduction), we performed the binding assay of DP2246 and DP2246mut (DP2246, in which S2246L mutation is introduced) to RyR2 using the peptide-mediated site-directed MCA labeling technique. 6, 9 The fluorescence labeling mediated by DP2246mut is also site-specific to the K201-binding domain, as indicated by both cold-chase and antibody-chase experiments, but, importantly, the intensity of Protein kinase A phosphorylation at Ser2808 in ryanodine receptor (RyR2) (P-Ser2808-RyR2) and local Ca 2ϩ release events in saponin-permeabilized cardiomyocytes. A, Comparison of P-Ser2808-RyR2 in knockin (KI) and wild-type (WT) cardiomyocytes. In the presence of cAMP (1 mol/L), okadaic acid (1 mol/L), and CaMKII inhibitor KN-93 (1 mol/L), KI and WT cardiomyocytes were incubated in the lysis buffer and centrifuged. Then the supernatant fraction containing crude homogenate was used for phosphorylation assay. N indicates the number of cell lysates from 3 to 4 hearts. B, Representative line-scan images of cardiomyocytes after addition of cAMP (0.1 to 1 mol/L), at 30 nmol/L [Ca 2ϩ ] buffered by 0.5 mmol/L EGTA. C, The plots of Ca 2ϩ spark frequency vs sarcoplasmic reticulum (SR) Ca 2ϩ content. SR Ca 2ϩ content was measured by addition of 10 mmol/L caffeine. To obtain the data at lower SR Ca 2ϩ contents, thapsigargin was added to the cardiomyocytes. Then both Ca 2ϩ sparks and SR Ca 2ϩ content were measured at 3, 5, and 10 minutes after the addition of thapsigargin (WT: nϭ4 to 5 hearts; KI: nϭ4 to 5 hearts). D, Effect of protein kinase A phosphorylation on Ca 2ϩ spark frequency during inhibition of SR Ca 2ϩ uptake in WT and S2246L/ϩ KI saponin-permeabilized cardiomyocytes. For protein kinase A phosphorylation of RyR2, both cAMP (1 mol/L) and okadaic acid (1 mol/L) were added to the cardiomyocytes at 30 nmol/L [Ca 2ϩ ] buffered by 0.5 mmol/L EGTA. Two minutes after the addition of cAMP, the added cAMP was washed away to prevent further protein kinase A phosphorylation. Then thapsigargin (0.3 mol/L) was added. One minute later, line-scanned images were obtained (WT: nϭ4 to 5 hearts; KI: nϭ4 to 5 hearts). E, The dependence of Ca 2ϩ spark frequency on SR Ca 2ϩ content in the absence or in the presence of DPc10 or dantrolene. Arrow indicates the shift of the data points in the absence or in the presence of DPc10 (50 mol/L) or dantrolene (1 mol/L) (WT: nϭ4 to 5 hearts; KI: nϭ4 to 5 hearts). F, The dependence of Ca 2ϩ spark frequency on SR Ca 2ϩ content in the absence or in the presence of K201 (1 mol/L) (WT: nϭ4 to 5 hearts; KI: nϭ4 to 5 hearts).
the MCA label of RyR2 is significantly higher than that of the DP2246-mediated labeling ( Figure 5A) .
To assess the affinity of binding of DP2246 to its partner domain, we plotted the extent of peptide-mediated sitedirected MCA fluorescence labeling of RyR2 as a function of the concentration of DP2246 or DP2246mut ( Figure 5B ). The apparent K d of peptide binding to the K201-binding domain was 0.09 mol/L with DP2246mut and 0.3 mol/L with DP2246, indicating that the S2246L mutation in the 2246 domain produced a significant enhancement of the interaction of DP2246 with its target domain (ie, K201binding domain).
In Vivo DP2246 Binding in Wild-Type and Knockin Cardiomyocytes
To assess the peptide binding to RyR2 in in vivo conditions, we fluorescently labeled DP2246 or DP2246mut with Oregon Green and introduced them into saponin-permeabilized cardiomyocytes. In WT cardiomyocytes, both the DP2246 binding signal and the DP2246mut binding signal were detected as green bands localized along the sarcomeres ( Figure 6 ). As shown in the middle panel of Figure 6 , DP2246mut showed higher binding affinity than DP2246 in the WT cardiomyocytes. In contrast, the fluorescence signal of both DP2246 and DP2246mut was barely detectable in the knockin cardiomyocytes. The plot of the intensity of the fluorescence along the sarcomeres (see Methods) as a function of the concentration of DP2246 (or DP2246mut) ( Figure 6 ; bottom) shows that in the WT cardiomyocytes, maximal binding of both peptides takes place at 3 mol/L peptides (K d with DP2246mut probe, 0.08 mol/L; K d with DP2246 probe, 0.14 mol/L). In the knockin cardiomyocytes, however, the binding is very partial even at the maximal concentration of the peptide we tested (3 mol/L). This suggests that the S2246L mutation leads to an abnormally strong interaction between the 2246 domain and the K201 domain, which precludes the binding of DP2246 and DP2246mut to the K201 domain of knockin RyR2.
Mutation-Induced Aberrant Tight Interaction of the 2246 Domain/K201-Binding Domain in S2246L/؉ Knockin Cardiomyocytes Causes Aberrant Unzipping of the Domain Switch
To investigate whether the domain switch is defective in S2246L/ϩ knockin mice, we adopted the fluorescence quench technique, 6, 9 which permits us to spectroscopically monitor whether the domains are zipped or unzipped.
As in our previous study, 13 only Data Supplement of Reference 11). As shown previously, in a zipped configuration of the domain switch, the attached MCA probe is inaccessible to a large fluorescence quencher QSY-bovine serum albumin conjugate; in an unzipped configuration, because of an opened gap between the interacting domains, the quencher becomes accessible to the attached MCA probe to quench the MCA fluorescence. In agreement with our previous study, 13 the extent of fluorescence quenching (K Q : the Stern-Volmer quenching constant determined from the slope of the plot, which is a measure of the extent of domain unzipping) of the MCA increased when the WT SR was treated with domain unzipping peptide DPc10 ( Figure 7A ). In the knockin (S2246L/ϩ) SR, on the other hand, the K Q showed a high value even before the addition of DPc10, which was comparable to the level that was reached by addition of DPc10 to the WT SR; the addition of DPc10 to the knockin SR produced no further increase in the K Q value ( Figure 7B) . These results suggest that S2246L mutation in the 2246 domain produced an allosteric effect on the domain switch, making it unzip, which is the same net result as would have been produced by the domain switch mutation R2474S.
Addition of dantrolene or K201 to the WT SR reduced the K Q , indicating that the defective, or unzipped, configuration of the domain switch that had been produced by DPc10 treatment was restored to a normal zipped configuration ( Figure 7A ). Addition of dantrolene to the knockin SR also reduced the K Q , indicative of recovered normal zipped configuration ( Figure 7B ). However, K201 was without effect on knockin SR ( Figure 7B) , presumably owing to the fact that the interaction between the 2246 domain and the K201-binding domain was so tight that K201 was inaccessible to the drug-binding domain.
The in vitro and in vivo assays of DP2246 binding to RyR2 (Figures 5 and 6 ) and the fluorescence quench assay of the domain switch ( Figure 7B ) suggest that the S2246L mutation causes aberrant zipping between the 2 subdomains within the central domain (namely, the 2246 domain and the K201binding domain), and this produced unzipping of the domain switch in an allosterically coupled manner. To test this postulated conformational coupling between the 2 regions (namely, domain zipping of the 2246 domain/K201-binding domain pair and reciprocally coupled domain unzipping of the domain switch), we performed site-specific MCA labeling of the K201 domain of the WT RyR2. We then performed the fluorescence quench assay using QSY-bovine serum albumin, following the same principle as described above. As shown in Figure 7A (right) , unzipping of the domain switch by DPc10 produced zipping of the 2246 domain/ K201 domain pair, as evidenced by a significant reduction in the K Q . Addition of dantrolene (50 mol/L), which completely restored the normal zipped state of the domain switch ( Figure 7A; left) , produced no appreciable effect on the 2246 domain/K201-binding domain interaction ( Figure  7A ; right). However, K201 (1 mol/L) completely restored the normal unzipped state of the 2246 domain/ K201-binding domain pair from the DPc10-induced zipped state ( Figure 7A; right) .
In the knockin RyR2, DP2246 was virtually inaccessible to the K201-binding domain because of tight interaction of the in vivo 2246 domain with the K201-binding domain, as described above. For this reason, we could not perform site-specific fluorescent labeling for the fluorescence quench assay of the 2246 domain/K201-binding domain interaction. However, in light of the data shown in Figure  7B , we assume that the addition of DPc10 to the knockin RyR2 would produce no further change because unzipping of the domain switch and the coupled zipping of the 2246 domain/K201-binding domain pair would have already taken place.
FKBP12.6 Binding to the RyR2 Remains Unaltered in Knockin RyR2 Mice
According to several reports, 19, 20 dissociation of RyR2-bound FKBP12.6 and resultant channel destabilization may be involved in both heart failure and lethal arrhythmia. We examined whether the CPVT mutation produced any effect on the RyR2-bound FKBP12.6 using a pull-down assay. As shown in Figure IV in the online-only Data Supplement, there was no significant difference in the amount of RyR2-bound FKBP12.6 between WT and knockin mice.
Discussion
A considerable body of evidence accumulated over recent years suggests that mutation-linked RyR2 defects cause SR Ca 2ϩ leak, which triggers delayed afterdepolarization and ultimately leads to CPVT. 2 Recently, several groups developed knockin mouse models harboring several different point mutations of RyR2 corresponding to the CPVT mutations of human patients (R4496C, 15 R176Q, 16 and R2474S 13, 17 ) and have shown that these mutations produce phenotypes of CPVT similar to those of human patients. The fact that these point mutations produce almost identical phenotypes of CPVT regardless of their locations within the RyR2 suggests that a mutation introduced into a particular location produces a global impact on the channel regulation mechanism (eg, by mediation of defective interdomain interaction in its local area first and then by coupled global conformational change of the RyR2). However, little work has been done in this new area of exploration.
The important new concept deduced from the present study, summarized in Figure 8 , is that the S2246L mutation that is introduced into the region of RyR2, different from that of the aforementioned R2474S mutation, causes an abnormally tight interaction (zipping) of a new interacting domain pair (namely, 2 subdomains: 2246 domain/K201binding domain [2114 to 2149]) located in the central domain and that this intersubdomain interaction is coupled with unzipping of the domain switch in an allosteric manner. Thus, the S2246L mutation ends up with aberrant unzipping of the domain switch, then produces the same type of channel dysfunction and CPVT phenotypes as those produced by the R2474S mutation. This concept is supported by the following pieces of evidence. First, DP2246, a peptide corresponding to the 2246 domain (2232 to 2266), was found to bind with the 2114 to 2149 region of RyR2, the previously identified K201-binding domain. 11 This suggests that there is an interaction between the 2246 domain and the K201-binding domain. As shown in the experiment with WT SR, the binding affinity of DP2246mut to RyR2 was much higher than that of DP2246, suggesting that the mutation induces a tight zipping of this interacting subdomain pair. In support of this view, DP2246 -Oregon Green was not accessible to its binding site in the knockin cardiomyocytes, although it was accessible in the WT cardiomyocytes. Second, DPc10, the central domain peptide that binds to the N-terminal domain and unzips the domain switch, 9, 13 induced domain zipping between the 2246 domain and its partner K201binding domain, indicating again that reciprocal conformational changes in the 2 regions are tightly coupled. Importantly, in the knockin RyR2, DPc10 was without effect; this is because the domain switch had already been unzipped owing to the allosteric coupling with the tightly zipped 2246 domain/K201-binding domain pair. Third, the S2246L mutation produced CPVT phenotypes identical to those produced by the R2474S mutation. Thus, the threshold of SR Ca 2ϩ load for channel activation (determined as increased Ca 2ϩ sparks) was markedly reduced in both the S2246L and the R2474S knockin cardiomyocytes. The same phenotype could be reproduced in the WT cardiomyocytes by experimentally unzipping the domain switch with DPc10. Thus, the present study provides preliminary evidence for a more generalized hypothesis that critical mutation in a particular area of the RyR2 causes defective interdomain interaction in its vicinity, which is then linked to a global conformational change that leads to channel activation by mediation of the allosteric conformational coupling mechanism. This would account for the fact that most of all of the CPVT mutations in different locations of RyR2 investigated in transgenic mouse models of CPVT have produced a virtually identical type of channel disorder and CPVT phenotypes. 13, [15] [16] [17] One of the 3 mutations investigated in the literature of the transgenic mouse models of CPVT, R4496C, 15 is localized in the "I" domain (3772 to 4610), whose steady interaction with the transmembrane channel region seems to play an important role in normal channel regulation. 21, 22 On the basis of this new expanded concept, we postulated that the I domain/channel domain interaction is coupled with the conformational changes in the domain switch and the 2246 domain/K201binding domain pair, and mutation-caused defective interdomain interaction in any of these regions is transmitted to the channel as a pathogenic signal.
One of the most important aspects in the present study is the finding that dantrolene corrected the defective unzipped state of the domain switch ( Figure 7) and then inhibited exercise-induced VT in the S2246L knockin mice (Figure 1 ). Because the dantrolene binding site is localized in the 600 to 620 residue region of the N-terminal domain of RyR2, 12 this indicates that dantrolene binding to its binding site corrected defective unzipping of the interacting N-terminal domain/central domain pair that had been produced by the S2246L mutation in the 2246 domain. As mentioned above, the mutation in the 2246 domain tightens its interaction with the K201-binding domain, and this local conformational change causes domain unzipping in the domain switch by the mechanism of conformational coupling between these 2 regions. Conversely, dantrolenemediated correction of aberrant unzipped configuration of the domain switch restores a normal stabilized state of the channel and stops VT, even though the drug produced virtually no effect on the 2246 domain/K201-binding domain interaction. We have shown previously in the canine heart failure model that dantrolene corrects defective unzipping between the N-terminal domain and the central domain to a normal zipped state and prevents the development of heart failure inducible by ventricular pacing. 12 Thus, it appears that defective interdomain interaction of the domain switch is a source mechanism underlying CPVT and heart failure and provides a key target of therapeutic treatment.
Although the R2474S and S2246L mutations produce basically identical impacts on the structure and function of the RyR2 as described above, there are delicate differences in the 2 aspects: (1) the response to PKA phosphorylation and (2) the pharmacological effect of K201. First, we reported previously that the R2474S mutation caused a partial unzipping of the domain switch, and on PKA phosphorylation at Ser2808 of RyR2, the domain switch was unzipped to a "full" extent. 13 The S2246L/ϩ knockin RyR2, on the other hand, showed a nearly maximal extent of domain unzipping under baseline conditions, accompanied by increased Ca 2ϩ spark frequency with reduced SR Ca 2ϩ content; consequently, PKA phosphorylation produced no further domain unzipping and hence no further effect on Ca 2ϩ spark frequency ( Figure 2D) . Second, as we demonstrated previously in the studies of a canine heart failure model, 11 K201 binding to its binding domain interfered with the interaction between the K201-binding domain and the 2246 domain and corrected channel dysfunctions of RyR2 of the failing heart. In the R2474S/ϩ knockin mouse model, K201 as well as dantrolene suppressed PKA phosphorylation-dependent channel activation (H. Uchinoumi, MD, PhD, et al, unpublished data, 2010). In the S2246L/ϩ knockin mouse model, however, K201 showed no appreciable corrective effect on both domain switch unzipping and channel activation ( Figure 2F ), although dantrolene produced the expected effects. These differences, as outlined above, may be accounted for by the fact that the S2246L mutation causes an excessively tight interaction of the K201-binding domain/ 2246 domain pair, which results in (1) facilitated unzipping of the domain switch by the conformational coupling between the 2 regions and (2) the inaccessibility of the K201-binding domain for the drug binding owing to its tight interaction with the 2246 domain.
Taken together, conformational coupling of different regions of RyR2 may explain the fact that mutations in different areas of the receptor produce a similar phenotype. However, in view of the nonidentical effects of the 2 types of potential therapeutic agents described in this report, differences in the mode of interdomain interaction in those different areas, to which dantrolene and K201 bind, may result in the observed differences in their therapeutic efficacy.
The present studies do not include the potential contribution of CaMKII, although the use of KN-93 could be complicated by off-target effects that are unrelated to CaM-KII activity on the basis of similar experience with KN-93 on other ion channels. A further investigation is clearly needed to assess the role of CaMKII in mutation-linked local Ca 2ϩ events.
In conclusion, introduction of a human CPVT mutation S2246L into the mouse RyR2 induces aberrant activation of channel gating by forming abnormally tight domain-domain interaction between the 2 subdomains located in the central domain: the S2246L mutable domain (residue 2232 to 2266) and the K201-binding domain (residue 2114 to 2149). This produces a defective domain unzipping between the N-terminal (residue 1 to 600) domain and the central (residue 2000 to 2500) domain owing to the allosteric conformational coupling between the 2 sets of interacting domain pairs. The coupled conformational changes in these regions trigger diastolic Ca 2ϩ release and lethal arrhythmia. Dantrolene treatment corrected the defective interdomain interaction and prevented aberrant Ca 2ϩ release and CPVT, indicating that correction of the conformational disorder of RyR2 is a new therapeutic strategy for CPVT.
